Cook unveils CookBiodesign.com

Share this article:
Cook Medical launched a third website for physicians and consumers, this time focusing on a suite of tissue repair products.

The site, CookBiodesign.com, provides resources for physicians on specific medical procedures related to tissue repair, featuring animation and video, billing and coding info, PubMed links, and post-op guides for patients, among other things. Docs can also sign up for newsletter emails, and contact Cook reps directly from the sight. For patients, the site offers testimonial video and information about specific tissue conditions and treatments.

Andy Cron, VP of Cook's surgery division, said the site helps to present information to physicians that can be difficult to communicate through a sales rep.

“It takes time to educate physicians…and it's very difficult to find time with them,” said Cron.

Cook launched the site during the American College of Surgeons meeting (Oct 11-15), and is promoting it through optimized keywords and direct mail to over 30,000 surgeons. CookBiodesign.com was built through a partnership with Digital Influence Group, which also worked on CookARTLab.com and MensHealthPD.com. Cron said the company is considering social media activities for the site, including Twitter.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...